Contact Us
Drug Search Results
More Filters [+]

Becatecarin

Alternative Names: becatecarin
Latest Update: 2014-05-23
Latest Update Note: Clinical Trial Update

Product Description

Becatecarin (rebeccamaycin analogue-RA) is an anti-tumor antibiotic with inhibitory activity against both topoisomerase II and I as well as DNA intercalating properties. (Sourced from: https://ascopubs.org/doi/10.1200/jco.2008.26.15_suppl.19060)

Mechanisms of Action: TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Helsinn Healthcare
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Becatecarin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Biliary Tract Cancer

Phase 2: Gallbladder Cancer|Cholangiocarcinoma|Colorectal Cancer|Liver Cancer|Bile Duct Cancer|Primary Central Nervous System Lymphoma|Retinoblastoma|Brain Stem Cancer|Neuroblastoma|Sarcoma|Small Cell Lung Cancer|Male Breast Cancer|Renal Cell Carcinoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Kidney Cancer

Phase 1: Juvenile Myelomonocytic Leukemia,|Blast Crisis|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Anemia, Refractory, with Excess of Blasts|Acute Lymphoid Leukemia|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia|Acute Monocytic Leukemia|Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelodysplastic Syndrome|Anemia, Aplastic|Chronic Lymphoid Leukemia|Acute Myelomonocytic Leukemia|Preleukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCI-2012-02587

P2

Terminated

Small Cell Lung Cancer

2008-04-01

NCI-2012-02609

P1

Completed

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Blast Crisis|Juvenile Myelomonocytic Leukemia,|Anemia, Refractory, with Excess of Blasts|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Acute Myelomonocytic Leukemia|Preleukemia|Chronic Lymphoid Leukemia|Myelodysplastic Syndrome|Anemia, Aplastic

2007-01-01

XL119-001

P3

Terminated

Biliary Tract Cancer

2006-11-01

CDR0000066852

P2

Completed

Neuroblastoma

2006-09-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions